CA-ALTIUM-LLC
4.6.2020 09:02:08 CEST | Business Wire | Press release
From home offices to virtual workplaces, the working environment has changed. For the Printed Circuit Board (PCB) design industry, Altium has helped make the transition seamless, empowering collaboration across every aspect of the design process. With Altium 365, the world’s only cloud-based platform for PCB design and realization, many of Altium’s customers were able to stay in motion even during the most challenging times.
As the world gets back to business, Altium is making it easy for PCB designers to continue to work from anywhere and connect with anyone.
“The workplace is more distributed than ever before, and at the same time our customers are dealing with unprecedented financial challenges,” says Ted Pawela, Altium’s COO. “We want to help the industry get back on track by making it easier than ever before to get the tools they need for PCB design, and work collaboratively in distributed work environments.”
Coming Together Without Impacting Workflow
Altium’s newest cloud-based platform, Altium 365, creates a connected experience throughout the PCB development and manufacturing process, making it easy to share PCB designs and collaborate in real-time with anyone - in any time zone, at any company, from anywhere - as the design evolves.
The platform has proven to be essential for PCB designers worldwide, including the teams working on the Open Source Ventilator Project , a global coalition of engineers, designers and medical practitioners. With Altium 365, PCB designers were able to co-design with mechanical engineers, in real-time via an easy online platform to finalize the designs.
As Douglas Karnazes, Founder and CEO of Velocity Research and member of the Open Source Ventilator Project elaborates, ‘When you have 3,000 people working on a project, labor and software is unlimited; the only limitation is time. We needed close collaboration with this many people, working from all over the world, all working from home, and Altium 365 helped pull everyone together.”
Salt Lake City’s Cirris Systems adopted Altium 365 just before workspaces shifted from physical to virtual. The need for remote work options would have been overwhelming for Cirris System’s one-man IT department, but with Altium 365, the company was able to transition to remote work without the need for new servers, VPNs or any downtime.
As Orlan Thatcher, Board Layout Specialist at Cirrius Systems, elaborates, “Our electrical engineers and myself have been using Altium 365 every day from our homes to do everything from sharing designs to preserving tight revision and process controls, that our bigger aerospace and aviation clients now expect.”
Altium Designer users do not have to change the way they work today to take advantage of Altium 365. The PCB design team at SkyShips , a Tier One automotive manufacturer of Infotainment systems, is using Altium 365 to align the global engineering team during the entire development process.
“We use the Altium 365 workspaces as a way to keep all our components, designs and projects all in one place, so that everyone is working from the same source of information. We are able to design faster with teams at different locations, “ stated Chris Brawn, Senior Design Engineer at SkyShips.
Making PCB Design Tools Accessible for Everyone
Altium has rolled out several initiatives to keep the electronics industry moving forward, including aggressive pricing for Altium Designer perpetual licenses with Altium 365 subscriptions. Altium is also allowing customers to pay in installments over a 12-month period, for those customers whose businesses are strapped for cash.
The newly launched Altium Designer Refer-a-Friend Program is another exciting opportunity for users to share their passion for Altium’s tools with their friends and colleagues and be rewarded. This newly launched program allows users to refer colleagues to purchase Altium Designer via a unique referral link accessible for current Altium Designer customers. When used to purchase a new license of Altium Designer, participants earn cash rewards.
ABOUT ALTIUM
Altium LLC (ASX:ALU ), a global software company headquartered in San Diego, Calif., is accelerating the pace of innovation through electronics. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.
The growing demand for smart and connected products is driving advancements in electronics technology. Design trends are demonstrating the need for minimizing power, reducing package size and energy consumption, and prioritizing high-speed design. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers, from idea to board. Users are at the center of Altium’s R&D and business operations. With its unique Business-to-User approach, Altium is focused on developing software that is easy to use and implement, with solutions that enable innovation and deliver industry-leading user productivity. Products include Altium Designer® , Altium Concord Pro™, Altium 365® , Altium NEXUS® , CircuitMaker® , CircuitStudio® , Octopart® , and TASKING® . To learn more about Altium, visit www.altium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200604005247/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
